This study presents an innovative dual-targeting design to address immune rejection and antigen escape in allogeneic CAR-T cell therapy, providing critical experimental evidence for universal cell therapy strategies in B-cell malignancies and autoimmune diseases.
Literature Overview
The paper titled 'Allogeneic CD19 CAR T cells armed with an anti-rejection CD70 CAR overcome antigen escape and evade alloimmune responses,' published in Nature Communications, systematically investigates how co-expression of a CD70-specific chimeric antigen receptor (CAR) can enhance the persistence and anti-tumor activity of allogeneic CD19 CAR-T cells. The authors developed a novel CD70 CAR variant (CD70z CAR) designed to eliminate activated alloreactive lymphocytes, thereby preventing host immune rejection. This strategy not only improves CAR-T cell survival in vivo but also effectively counters tumor escape caused by antigen heterogeneity. The therapeutic potential of these bispecific CAR-T cells was further validated in multiple humanized mouse models for B-cell non-Hodgkin lymphoma and systemic lupus erythematosus (SLE).Background Knowledge
CAR-T cell therapy has shown remarkable efficacy in hematologic malignancies and autoimmune diseases. However, autologous CAR-T therapies face limitations such as lengthy manufacturing times and poor T-cell quality. While allogeneic 'off-the-shelf' CAR-T cells offer a solution, they are vulnerable to host T-cell and NK-cell-mediated rejection, resulting in poor persistence. Additionally, antigen escape—particularly in CD19-negative relapses—remains a major cause of CAR-T treatment failure. Current strategies like TCR or HLA-I knockout reduce graft-versus-host disease (GvHD) or T-cell rejection but may trigger NK-cell-mediated 'missing self' killing. Thus, there is an urgent need for novel approaches that simultaneously prevent immune rejection and overcome antigen heterogeneity. This study focuses on CD70—a costimulatory molecule transiently expressed on activated T cells, B cells, and dendritic cells, with limited expression in healthy tissues—making it an ideal immunomodulatory target. By targeting CD70 to eliminate activated alloreactive lymphocytes, the authors propose a dual CAR-T cell design that combines anti-rejection and broad anti-tumor functions.
Research Methods and Experiments
The authors first constructed multiple CD70 CAR variants in vitro and identified CD70z CAR—a version lacking the rituximab-recognizable epitope—with high expression and low exhaustion phenotype. In mixed lymphocyte reaction (MLR) assays, T cells expressing CD70z CAR selectively eliminated activated CD70+ allogeneic T and NK cells, significantly improving survival of allogeneic T cells. Subsequently, the team engineered bispecific CD19/CD70 CAR-T cells using TRAC locus-targeted integration to ensure stable expression. In a Raji lymphoma model, these dual-targeting CAR-T cells controlled tumor growth even in the absence of CD19 antigen. Furthermore, in humanized mouse models, the cells effectively eliminated B cells and CD70+ T cells derived from SLE patients, significantly reducing serum IgG and IgM levels, highlighting their therapeutic potential in autoimmune diseases.Key Conclusions and Perspectives
Research Significance and Prospects
This study introduces a novel strategy for developing 'universal' allogeneic CAR-T products by enabling immune self-protection through CD70 targeting, reducing dependence on intensive lymphodepletion regimens and lowering treatment-related toxicity. Particularly in autoimmune diseases, this dual-targeting CAR-T approach not only eliminates pathogenic B cells but also modulates aberrantly activated T cells, potentially achieving long-term remission. From a drug development perspective, the design is highly modular and adaptable to other target combinations, with potential applications in solid tumors or other immune-mediated disorders. Moreover, the transient expression of CD70 may minimize off-target killing of resting lymphocytes, enhancing safety. Future studies should evaluate long-term B-cell aplasia and impacts on antiviral immunity, but this work provides a solid foundation for clinical translation of CAR-T therapies.
Conclusion
This study innovatively integrates anti-rejection functionality directly into CAR-T cells, proposing a CD19/CD70 bispecific CAR-T cell strategy that effectively addresses two major challenges in allogeneic CAR-T therapy—immune rejection and antigen escape. The cells demonstrate superior persistence and broad anti-tumor activity across multiple humanized models, and notably reduce autoantibody levels in SLE models, highlighting their immense potential in treating autoimmune diseases. Compared to conventional CAR-T cells, this design reduces reliance on intensive lymphodepletion, improving both safety and applicability. From bench to bedside, this research offers a replicable engineering framework for developing 'off-the-shelf' CAR-T products, potentially reshaping the treatment landscape for B-cell malignancies and autoimmune disorders. Future clinical trials will further validate its safety and efficacy, advancing universal cell therapy into a new era.
